[EN] MODULATORS OF EUKARYOTIC INITIATION FACTOR 2<br/>[FR] MODULATEURS DU FACTEUR 2 D'INITIATION EUCARYOTE
申请人:DENALI THERAPEUTICS INC
公开号:WO2019183589A1
公开(公告)日:2019-09-26
The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.
[EN] 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS<br/>[FR] DÉRIVÉS DE 4-BENZYLAMINOPYRROLIDINE 1,2-DISUBSTITUÉE COMME INHIBITEURS DE CETP UTILES POUR LE TRAITEMENT DE MALADIES TELLES QUE L'HYPERLIPIDÉMIE OU L'ARTÉRIOSCLÉROSE
申请人:NOVARTIS AG
公开号:WO2009071509A1
公开(公告)日:2009-06-11
The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors
申请人:Novartis AG
公开号:US08193349B2
公开(公告)日:2012-06-05
The present invention provides a compound of formula (I):
wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
Method of inhibiting CETP activity with 4-benzylamino-1-carboxylacyl-piperidine derivatives
申请人:Mogi Muneto
公开号:US08420641B2
公开(公告)日:2013-04-16
The present invention provides a compound of formula (I):
wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.